EU confirms suspension of 700 products hit by Indian CRO issues
This article was originally published in Scrip
Executive Summary
Around 700 generic drugs will no longer be available in Europe from 21 August after the European Commission issued a decision confirming the products' suspension in light of concerns over data manipulation by the Indian CRO GVK Biosciences.